Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an ...

Issue 2: Life Support - How Ireland’s FDI base is preparing for the next wave in connected health Advanced optics, lighting, ...

Three cancer therapies were among the first two batches of drugs to receive vouchers through a new FDA program.

Next-generation weight loss pills are expected to hit the market next year, and drugmakers are working on medications with ...

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.